(Q42981051)

12 November 2017

Dose increase augments response rate to interferon-alpha in chronic hepatitis C. (English)

1 reference

12 November 2017

P Ferenci

1

1 reference

12 November 2017

R Stauber

2

1 reference

12 November 2017

A Propst

3

1 reference

12 November 2017

R Fiedler

4

1 reference

12 November 2017

C Müller

5

1 reference

12 November 2017

M Gschwantler

6

1 reference

12 November 2017

K Schütze

7

1 reference

12 November 2017

C Datz

8

1 reference

12 November 2017

G Judmaier

9

1 reference

12 November 2017

W Vogel

10

1 reference

12 November 2017

G J Krejs

11

1 reference

12 November 2017

A Gangl

12

1 reference

12 November 2017

1 December 1996

1 reference

Digestive Diseases and Sciences

12 November 2017

1 reference

12 November 2017

41

1 reference

12 November 2017

103S-108S

1 reference

12 November 2017

12 Suppl

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02087884

12 November 2017

0 references

cites work

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02087884

N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02087884

A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C.

21 January 2018

1 reference

12 December 2020

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

12 December 2020

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

12 December 2020

One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b

1 reference

12 December 2020

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

12 December 2020

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses.

1 reference

12 December 2020

Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study

1 reference

12 December 2020

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

1 reference

12 December 2020

Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.

1 reference

12 December 2020

Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C

1 reference

12 December 2020

Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France

1 reference

12 December 2020

Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group

1 reference

12 December 2020

Raising the dose of interferon does not improve the response in chronic hepatitis C.

1 reference

12 December 2020

High dose interferon alpha-2b therapy for chronic hepatitis C: an open label study of the response and predictors of response

1 reference

12 December 2020

Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial.

1 reference

12 December 2020

High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks

1 reference

12 December 2020

Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02087884

1 reference

12 November 2017

1 reference